Lai J - Search Results

1

Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.

Jiang T, Chen H, Zheng J, Du B, Yang B, Liu Q, Zhong D, Wang X, Wang H, Lin M, Lai J, Hou P, Lin X. Jiang T, et al. Among authors: lai j. Adv Ther. 2020 Jun;37(6):2829-2840. doi: 10.1007/s12325-020-01360-8. Epub 2020 May 7. Adv Ther. 2020. PMID: 32378072

2

Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment.

Lai J, Du B, Wang Y, Wu R, Yu Z. Lai J, et al. Onco Targets Ther. 2018 Dec 14;11:9111-9116. doi: 10.2147/OTT.S174877. eCollection 2018. Onco Targets Ther. 2018. PMID: 30588023 Free PMC article.

3

Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.

Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, Zhang J, Kong W, Huang X, Chen Y, Shi Y, Shi X, Zhao Z, Ni M, Lin X, Chen S, Wu X, Chen W, Song Z, Huang C. Yu Z, et al. Among authors: lai j. Oncologist. 2020 Nov;25(11):e1640-e1649. doi: 10.1634/theoncologist.2020-0519. Epub 2020 Jul 25. Oncologist. 2020. PMID: 32533785 Free PMC article. Clinical Trial.

4

Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.

Du B, Wen X, Wang Y, Lin M, Lai J. Du B, et al. Among authors: lai j. Int Immunopharmacol. 2020 Sep;86:106694. doi: 10.1016/j.intimp.2020.106694. Epub 2020 Jun 20. Int Immunopharmacol. 2020. PMID: 32570034

5

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.

Wu Y, Du B, Lv C, Ji X, Lan Y, Yao N, Zhu Y, Lai J. Wu Y, et al. Among authors: lai j. Ann Med. 2023;55(2):2243967. doi: 10.1080/07853890.2023.2243967. Ann Med. 2023. PMID: 37557185 Free PMC article.

6

The identification of genes associated T-cell exhaustion and construction of prognostic signature to predict immunotherapy response in lung adenocarcinoma.

Wu Y, Du B, Lin M, Ji X, Lv C, Lai J. Wu Y, et al. Among authors: lai j. Sci Rep. 2023 Aug 17;13(1):13415. doi: 10.1038/s41598-023-40662-z. Sci Rep. 2023. PMID: 37592010 Free PMC article.

7

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab.

Wu Y, Du B, Lv C, Ji X, Lai J. Wu Y, et al. Among authors: lai j. Ann Med. 2023;55(2):2257227. doi: 10.1080/07853890.2023.2257227. Ann Med. 2023. PMID: 37713583 Free PMC article.

8

Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.

Wu Y, Lv C, Lin M, Hong Y, Du B, Yao N, Zhu Y, Ji X, Li J, Lai J. Wu Y, et al. Among authors: lai j. Front Immunol. 2023 Nov 8;14:1297188. doi: 10.3389/fimmu.2023.1297188. eCollection 2023. Front Immunol. 2023. PMID: 38022521 Free PMC article.

9

Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma.

Wu Y, Yao N, Du B, Zhu Y, Ji X, Lv C, Lai J. Wu Y, et al. Among authors: lai j. J Cancer. 2024 Mar 11;15(9):2549-2560. doi: 10.7150/jca.91759. eCollection 2024. J Cancer. 2024. PMID: 38577587 Free PMC article.

10

Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study.

Lv C, Wu Y, Gu W, Du B, Yao N, Zhu Y, Zheng J, Hong Y, Lai J. Lv C, et al. Among authors: lai j. Front Immunol. 2024 Jun 7;15:1413204. doi: 10.3389/fimmu.2024.1413204. eCollection 2024. Front Immunol. 2024. PMID: 38911862 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,915 results

Search Page

Filters